瑞茂通(600180.SH):擬出資29.4億元與河南交投共設合資公司
格隆匯4月15日丨瑞茂通(600180.SH)公佈,本着“優勢互補、合作共贏”的原則,瑞茂通供應鏈管理股份有限公司擬與河南交通投資集團有限公司(簡稱“河南交投”)共同出資設立合資公司。經洽談推進,雙方於2022年4月15日在河南省鄭州市簽署《合作投資協議》。合資公司的名稱為:河南物產集團有限公司(最終名稱以工商登記機關核准登記的為準),註冊資本為人民幣60億元,其中河南交投認繳的註冊資本為人民幣30.6億元,佔合資公司註冊資本總額的51%;瑞茂通認繳的註冊資本為人民幣29.4億元,佔合資公司註冊資本總額的49%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.